Skip to content
10-Q

Quarterly Report

VITASPRING BIOMEDICAL CO. LTD.

0001640334-26-000076

← back to feed
Filed
Jan 13, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2024 · Jan 6, 2026 207.03M sh
Current Liabilities Q1 2024 · Apr 30, 2023 $3.16M
Current Liabilities Q1 2024 · Jan 31, 2023 $3.07M
Total Liabilities Q1 2024 · Apr 30, 2023 $3.21M
Total Liabilities Q1 2024 · Jan 31, 2023 $3.16M
Current Assets Q1 2024 · Apr 30, 2023 $263.39K
Current Assets Q1 2024 · Jan 31, 2023 $437.08K
Total Assets Q1 2024 · Apr 30, 2023 $548.54K
Total Assets Q1 2024 · Jan 31, 2023 $765.95K
Gross Profit Q1 2024 · Apr 30, 2023 $0
Gross Profit Q1 2024 · Apr 30, 2022 $568K
Cost Of Revenue Q1 2024 · Apr 30, 2023 $0
Cost Of Revenue Q1 2024 · Apr 30, 2022 $922K
Shares Diluted Q1 2024 · Apr 30, 2022 206.52M sh
Operating Cash Flow Q1 2024 · Apr 30, 2022 −$28.06K
Stockholders Equity Q1 2024 · Apr 30, 2022 $1.89M
Stockholders Equity Q1 2024 · Jan 31, 2022 $1.58M
Eps Diluted Q1 2024 · Apr 30, 2022 $0.00
Sga Expense Q1 2024 · Apr 30, 2022 $224.87K
Net Income Q1 2024 · Apr 30, 2022 $276.66K
Operating Income Q1 2024 · Apr 30, 2022 $343.13K
Revenue Q1 2024 · Apr 30, 2022 $1.49M